Tirzepatide may be suitable for adults who are classified as obese, with a body mass index (BMI) of 30 or higher, or those who are overweight with a BMI of 27 or higher and have related health conditions such as hypertension, type 2 diabetes, or dyslipidemia
Note that insulin or sulfonylurea doses may need reduction when used with tirzepatide due to increased hypoglycaemia risk
SGLT2 inhibitors work by inhibiting Sodium-Glucose Co-Transporter 2 (SGLT2), a protein in the kidneys
proposed that the research on the treatment for immune-mediated diseases, such as rheumatoid arthritis, should attempt to achieve a more comprehensive understanding of various disease-related biomarkers, conducting large-scale high-throughput data analysis, and identifying and quantifying the disease metabolites (37)
What are the potential side effects, and how can you ensure you're getting the best treatment